How muscle ribosomes may drive muscular dystrophy
Contribution of ribosome specialization to the pathophysiology of muscular dystrophy
Researchers are looking at whether a muscle-specific ribosomal protein called RPL3L helps keep muscles healthy and if restoring it could slow muscular dystrophy in adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11229635 on NIH RePORTER |
What this research studies
This work focuses on tiny protein-making machines in muscle cells called ribosomes and a muscle-specific piece named RPL3L that can replace a more common ribosomal protein (RPL3). Scientists will compare how ribosomes with RPL3L versus RPL3 make mitochondrial and contractile proteins in healthy and dystrophic muscle. They plan lab-based experiments using cells and animal models to see whether losing RPL3L leads to imbalanced protein production and earlier mitochondrial decline. The team will also attempt to restore the muscle-specific ribosomal protein to test whether that improves muscle function.
Who could benefit from this research
Good fit: Adults (21+) with a diagnosis of muscular dystrophy, particularly those in earlier stages of disease, would be the most relevant population for these findings.
Not a fit: People without muscular dystrophy or those with non-dystrophic or very advanced muscle disease are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could reveal a new biological target and pathway to slow or improve muscle decline in people with muscular dystrophy.
How similar studies have performed: Ribosome specialization is a relatively new idea with supportive early lab evidence, but directly restoring RPL3L as a therapy is novel and unproven.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Wen, Yuan — University of Kentucky
- Study coordinator: Wen, Yuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.